O	0	10	Prognostic	Prognostic	JJ	B-NP
O	11	23	significance	significance	NN	I-NP
O	24	26	of	of	IN	B-PP
O	27	32	TRAIL	TRAIL	NN	B-NP
O	33	42	signaling	signaling	NN	I-NP
O	43	52	molecules	molecule	NNS	I-NP
O	53	55	in	in	IN	B-PP
B-Cancer	56	61	stage	stage	NN	B-NP
I-Cancer	62	64	II	II	CD	I-NP
I-Cancer	65	68	and	and	CC	I-NP
I-Cancer	69	72	III	III	CD	I-NP
I-Cancer	73	83	colorectal	colorectal	JJ	I-NP
I-Cancer	84	90	cancer	cancer	NN	I-NP
O	90	91	.	.	.	O

O	92	99	PURPOSE	PURPOSE	NN	B-NP
O	99	100	:	:	:	O

O	101	103	We	We	PRP	B-NP
O	104	114	previously	previously	RB	B-ADVP
O	115	120	found	find	VBD	B-VP
O	121	125	that	that	IN	B-SBAR
O	126	134	cellular	cellular	JJ	B-NP
O	135	140	FLICE	FLICE	NN	I-NP
O	140	141	-	-	HYPH	B-NP
O	141	151	inhibitory	inhibitory	JJ	I-NP
O	152	159	protein	protein	NN	I-NP
O	160	161	(	(	(	O
O	161	162	c	c	NN	O
O	162	163	-	-	HYPH	O
O	163	167	FLIP	FLIP	NN	B-NP
O	167	168	)	)	)	O
O	168	169	,	,	,	O
O	170	177	caspase	caspase	NN	B-NP
O	178	179	8	8	CD	I-NP
O	179	180	,	,	,	O
O	181	184	and	and	CC	O
O	185	190	tumor	tumor	NN	B-NP
O	191	199	necrosis	necrosis	NN	I-NP
O	200	206	factor	factor	NN	I-NP
O	206	207	-	-	HYPH	B-VP
O	207	214	related	relate	VBN	B-NP
O	215	224	apoptosis	apoptosis	NN	I-NP
O	224	225	-	-	HYPH	O
O	225	233	inducing	induce	VBG	B-VP
O	234	240	ligand	ligand	NN	B-NP
O	241	242	(	(	(	O
O	242	247	TRAIL	TRAIL	NN	B-NP
O	247	248	)	)	)	O
O	249	257	receptor	receptor	NN	B-NP
O	258	259	2	2	CD	I-NP
O	260	261	(	(	(	O
O	261	264	DR5	DR5	NN	B-NP
O	264	265	)	)	)	O
O	266	269	are	be	VBP	B-VP
O	270	275	major	major	JJ	B-NP
O	276	286	regulators	regulator	NNS	I-NP
O	287	289	of	of	IN	B-PP
B-Cell	290	294	cell	cell	NN	B-NP
O	295	304	viability	viability	NN	I-NP
O	305	308	and	and	CC	I-NP
O	309	321	chemotherapy	chemotherapy	NN	I-NP
O	321	322	-	-	HYPH	B-NP
O	322	329	induced	induce	VBN	I-NP
O	330	339	apoptosis	apoptosis	NN	I-NP
O	340	342	in	in	IN	B-PP
B-Cancer	343	353	colorectal	colorectal	JJ	B-NP
I-Cancer	354	360	cancer	cancer	NN	I-NP
O	360	361	.	.	.	O

O	362	364	In	In	IN	B-PP
O	365	369	this	this	DT	B-NP
O	370	375	study	study	NN	I-NP
O	375	376	,	,	,	O
O	377	379	we	we	PRP	B-NP
O	380	390	determined	determine	VBD	B-VP
O	391	394	the	the	DT	B-NP
O	395	405	prognostic	prognostic	JJ	I-NP
O	406	418	significance	significance	NN	I-NP
O	419	421	of	of	IN	B-PP
O	422	423	c	c	NN	B-NP
O	423	424	-	-	HYPH	O
O	424	428	FLIP	FLIP	NN	B-NP
O	428	429	,	,	,	O
O	430	437	caspase	caspase	NN	B-NP
O	438	439	8	8	CD	I-NP
O	439	440	,	,	,	I-NP
O	441	446	TRAIL	TRAIL	NN	I-NP
O	447	450	and	and	CC	I-NP
O	451	454	DR5	DR5	NN	I-NP
O	455	465	expression	expression	NN	I-NP
O	466	468	in	in	IN	B-PP
B-Tissue	469	476	tissues	tissue	NNS	B-NP
O	477	481	from	from	IN	B-PP
O	482	490	patients	patient	NNS	B-NP
O	491	495	with	with	IN	B-PP
B-Cancer	496	501	stage	stage	NN	B-NP
I-Cancer	502	504	II	II	CD	I-NP
I-Cancer	505	508	and	and	CC	I-NP
I-Cancer	509	512	III	III	CD	I-NP
I-Cancer	513	523	colorectal	colorectal	JJ	I-NP
I-Cancer	524	530	cancer	cancer	NN	I-NP
O	530	531	.	.	.	O

O	532	544	EXPERIMENTAL	EXPERIMENTAL	JJ	B-NP
O	545	551	DESIGN	DESIGN	NN	I-NP
O	551	552	:	:	:	O

B-Tissue	553	559	Tissue	Tissue	NN	B-NP
O	560	571	microarrays	microarray	NNS	I-NP
O	572	576	were	be	VBD	B-VP
O	577	588	constructed	construct	VBN	I-VP
O	589	593	from	from	IN	B-PP
O	594	601	matched	match	VBN	B-NP
O	602	608	normal	normal	JJ	I-NP
O	609	612	and	and	CC	I-NP
B-Tissue	613	618	tumor	tumor	NN	I-NP
I-Tissue	619	625	tissue	tissue	NN	I-NP
O	626	633	derived	derive	VBN	B-VP
O	634	638	from	from	IN	B-PP
O	639	647	patients	patient	NNS	B-NP
O	648	649	(	(	(	O
O	649	650	n	n	NN	B-NP
O	651	652	=	=	SYM	B-VP
O	653	656	253	253	CD	B-NP
O	656	657	)	)	)	O
O	658	666	enrolled	enrol	VBN	B-VP
O	667	669	in	in	IN	B-PP
O	670	671	a	a	DT	B-NP
O	672	677	phase	phase	NN	I-NP
O	678	681	III	III	CD	I-NP
O	682	687	trial	trial	NN	I-NP
O	688	690	of	of	IN	B-PP
O	691	699	adjuvant	adjuvant	JJ	B-NP
O	700	701	5	5	CD	I-NP
O	701	702	-	-	HYPH	I-NP
O	702	714	fluorouracil	fluorouracil	NN	I-NP
O	714	715	-	-	HYPH	O
O	715	720	based	base	VBN	B-NP
O	721	733	chemotherapy	chemotherapy	NN	I-NP
O	734	740	versus	versus	IN	B-PP
O	741	754	postoperative	postoperative	JJ	B-NP
O	755	766	observation	observation	NN	I-NP
O	767	772	alone	alone	RB	B-ADVP
O	772	773	.	.	.	O

O	774	779	TRAIL	TRAIL	NN	B-NP
O	779	780	,	,	,	O
O	781	784	DR5	DR5	NN	B-NP
O	784	785	,	,	,	O
O	786	793	caspase	caspase	NN	B-NP
O	794	795	8	8	CD	I-NP
O	795	796	,	,	,	O
O	797	800	and	and	CC	O
O	801	802	c	c	NN	O
O	802	803	-	-	HYPH	O
O	803	807	FLIP	FLIP	NN	B-NP
O	808	818	expression	expression	NN	I-NP
O	819	825	levels	level	NNS	I-NP
O	826	830	were	be	VBD	B-VP
O	831	841	determined	determine	VBN	I-VP
O	842	844	by	by	IN	B-PP
O	845	865	immunohistochemistry	immunohistochemistry	NN	B-NP
O	865	866	.	.	.	O

O	867	874	RESULTS	RESULTS	NNS	B-NP
O	874	875	:	:	:	O

B-Cancer	876	886	Colorectal	Colorectal	JJ	B-NP
I-Cancer	887	893	tumors	tumor	NNS	I-NP
O	894	903	displayed	display	VBD	B-VP
O	904	917	significantly	significantly	RB	B-NP
O	918	924	higher	high	JJR	I-NP
O	925	935	expression	expression	NN	I-NP
O	936	942	levels	level	NNS	I-NP
O	943	945	of	of	IN	B-PP
O	946	947	c	c	NN	B-NP
O	947	948	-	-	HYPH	O
O	948	952	FLIP	FLIP	NN	B-NP
O	953	954	(	(	(	O
O	954	955	P	P	NN	B-NP
O	956	957	<	<	SYM	B-ADJP
O	958	959	0	0	CD	B-NP
O	959	960	.	.	.	I-NP
O	960	963	001	001	CD	I-NP
O	963	964	)	)	)	O
O	964	965	,	,	,	O
O	966	973	caspase	caspase	NN	B-NP
O	974	975	8	8	CD	I-NP
O	976	977	(	(	(	O
O	977	978	P	P	NN	B-NP
O	979	980	=	=	SYM	B-VP
O	981	982	0	0	CD	B-NP
O	982	983	.	.	SYM	I-NP
O	983	985	01	01	CD	I-NP
O	985	986	)	)	)	O
O	986	987	,	,	,	O
O	988	991	and	and	CC	O
O	992	995	DR5	DR5	NN	B-NP
O	996	997	(	(	(	O
O	997	998	P	P	NN	B-NP
O	999	1000	<	<	SYM	B-ADJP
O	1001	1002	0	0	CD	B-NP
O	1002	1003	.	.	.	I-NP
O	1003	1006	001	001	CD	I-NP
O	1006	1007	)	)	)	O
O	1007	1008	,	,	,	O
O	1009	1012	but	but	CC	O
O	1013	1018	lower	low	JJR	B-NP
O	1019	1025	levels	level	NNS	I-NP
O	1026	1028	of	of	IN	B-PP
O	1029	1034	TRAIL	TRAIL	NN	B-NP
O	1035	1036	(	(	(	O
O	1036	1037	P	P	NN	B-NP
O	1038	1039	<	<	SYM	B-ADJP
O	1040	1041	0	0	CD	B-NP
O	1041	1042	.	.	.	I-NP
O	1042	1045	001	001	CD	I-NP
O	1045	1046	)	)	)	O
O	1047	1055	compared	compare	VBN	B-PP
O	1056	1060	with	with	IN	B-PP
O	1061	1068	matched	match	VBN	B-NP
O	1069	1075	normal	normal	JJ	I-NP
B-Tissue	1076	1082	tissue	tissue	NN	I-NP
O	1082	1083	.	.	.	O

O	1084	1086	In	In	IN	B-PP
O	1087	1097	univariate	univariate	JJ	B-NP
O	1098	1106	analysis	analysis	NN	I-NP
O	1106	1107	,	,	,	O
O	1108	1114	higher	high	JJR	B-NP
O	1115	1120	TRAIL	TRAIL	NN	I-NP
O	1121	1131	expression	expression	NN	I-NP
O	1132	1134	in	in	IN	B-PP
O	1135	1138	the	the	DT	B-NP
B-Cancer	1139	1144	tumor	tumor	NN	I-NP
O	1145	1148	was	be	VBD	B-VP
O	1149	1159	associated	associate	VBN	I-VP
O	1160	1164	with	with	IN	B-PP
O	1165	1170	worse	worse	JJR	B-NP
O	1171	1178	overall	overall	JJ	I-NP
O	1179	1187	survival	survival	NN	I-NP
O	1188	1189	(	(	(	O
O	1189	1190	P	P	NN	B-NP
O	1191	1192	=	=	SYM	B-VP
O	1193	1194	0	0	CD	B-NP
O	1194	1195	.	.	.	O
O	1195	1198	026	026	CD	B-NP
O	1198	1199	)	)	)	O
O	1199	1200	,	,	,	O
O	1201	1205	with	with	IN	B-PP
O	1206	1207	a	a	DT	B-NP
O	1208	1213	trend	trend	NN	I-NP
O	1214	1216	to	to	TO	B-PP
O	1217	1226	decreased	decrease	VBN	B-NP
O	1227	1234	relapse	relapse	NN	I-NP
O	1234	1235	-	-	HYPH	O
O	1235	1239	free	free	JJ	B-NP
O	1240	1248	survival	survival	NN	I-NP
O	1249	1250	(	(	(	O
O	1250	1253	RFS	RFS	NN	B-NP
O	1253	1254	;	;	:	O
O	1255	1256	P	P	NN	B-NP
O	1257	1258	=	=	SYM	B-VP
O	1259	1260	0	0	CD	B-NP
O	1260	1261	.	.	SYM	I-NP
O	1261	1263	06	06	CD	I-NP
O	1263	1264	)	)	)	O
O	1264	1265	,	,	,	O
O	1266	1269	and	and	CC	O
O	1270	1276	higher	high	JJR	B-NP
B-Cancer	1277	1282	tumor	tumor	NN	I-NP
O	1283	1284	c	c	NN	I-NP
O	1284	1285	-	-	HYPH	B-NP
O	1285	1289	FLIP	FLIP	NN	I-NP
O	1290	1300	expression	expression	NN	I-NP
O	1301	1304	was	be	VBD	B-VP
O	1305	1315	associated	associate	VBN	I-VP
O	1316	1320	with	with	IN	B-PP
O	1321	1322	a	a	DT	B-NP
O	1323	1336	significantly	significantly	RB	I-NP
O	1337	1346	decreased	decrease	VBN	I-NP
O	1347	1350	RFS	RFS	NN	I-NP
O	1351	1352	(	(	(	O
O	1352	1353	P	P	NN	B-NP
O	1354	1355	=	=	SYM	B-VP
O	1356	1357	0	0	CD	B-NP
O	1357	1358	.	.	SYM	I-NP
O	1358	1361	015	015	CD	I-NP
O	1361	1362	)	)	)	O
O	1362	1363	.	.	.	O

O	1364	1369	Using	Use	VBG	B-VP
O	1370	1382	multivariate	multivariate	JJ	B-NP
O	1383	1393	predictive	predictive	JJ	I-NP
O	1394	1402	modeling	modeling	NN	I-NP
O	1403	1406	for	for	IN	B-PP
O	1407	1410	RFS	RFS	NN	B-NP
O	1411	1413	in	in	IN	B-PP
O	1414	1417	all	all	DT	B-NP
O	1418	1426	patients	patient	NNS	I-NP
O	1427	1430	and	and	CC	O
O	1431	1440	including	include	VBG	B-PP
O	1441	1444	all	all	DT	B-NP
O	1445	1455	biomarkers	biomarker	NNS	I-NP
O	1455	1456	,	,	,	O
O	1457	1460	age	age	NN	B-NP
O	1460	1461	,	,	,	O
O	1462	1471	treatment	treatment	NN	B-NP
O	1471	1472	,	,	,	O
O	1473	1476	and	and	CC	O
O	1477	1482	stage	stage	NN	B-NP
O	1482	1483	,	,	,	O
O	1484	1486	we	we	PRP	B-NP
O	1487	1492	found	find	VBD	B-VP
O	1493	1497	that	that	IN	B-SBAR
O	1498	1501	the	the	DT	B-NP
O	1502	1507	model	model	NN	I-NP
O	1508	1511	was	be	VBD	B-VP
O	1512	1523	significant	significant	JJ	B-ADJP
O	1524	1528	when	when	WRB	B-ADVP
O	1529	1532	the	the	DT	B-NP
O	1533	1537	mean	mean	JJ	I-NP
B-Cancer	1538	1543	tumor	tumor	NN	I-NP
O	1544	1545	c	c	NN	I-NP
O	1545	1546	-	-	HYPH	B-NP
O	1546	1550	FLIP	FLIP	NN	I-NP
O	1551	1561	expression	expression	NN	I-NP
O	1562	1567	score	score	NN	I-NP
O	1568	1571	and	and	CC	O
O	1572	1579	disease	disease	NN	B-NP
O	1580	1585	stage	stage	NN	I-NP
O	1586	1590	were	be	VBD	B-VP
O	1591	1599	included	include	VBN	I-VP
O	1600	1601	(	(	(	O
O	1601	1602	P	P	NN	B-NP
O	1603	1604	<	<	SYM	B-ADJP
O	1605	1606	0	0	CD	B-NP
O	1606	1607	.	.	.	I-NP
O	1607	1610	001	001	CD	I-NP
O	1610	1611	)	)	)	O
O	1611	1612	.	.	.	O

O	1613	1615	As	As	IN	B-SBAR
O	1616	1623	regards	regard	VBZ	B-VP
O	1624	1631	overall	overall	JJ	B-NP
O	1632	1640	survival	survival	NN	I-NP
O	1640	1641	,	,	,	O
O	1642	1645	the	the	DT	B-NP
O	1646	1653	overall	overall	JJ	I-NP
O	1654	1659	model	model	NN	I-NP
O	1660	1663	was	be	VBD	B-VP
O	1664	1674	predictive	predictive	JJ	B-ADJP
O	1675	1679	when	when	WRB	B-ADVP
O	1680	1684	both	both	CC	O
O	1685	1690	TRAIL	TRAIL	NN	B-NP
O	1691	1701	expression	expression	NN	B-NP
O	1702	1705	and	and	CC	O
O	1706	1713	disease	disease	NN	B-NP
O	1714	1719	stage	stage	NN	I-NP
O	1720	1724	were	be	VBD	B-VP
O	1725	1733	included	include	VBN	I-VP
O	1734	1735	(	(	(	O
O	1735	1736	P	P	NN	B-NP
O	1737	1738	<	<	SYM	B-ADJP
O	1739	1740	0	0	CD	B-NP
O	1740	1741	.	.	.	I-NP
O	1741	1744	001	001	CD	I-NP
O	1744	1745	)	)	)	O
O	1745	1746	.	.	.	O

O	1747	1758	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1758	1759	:	:	:	O

O	1760	1764	High	High	JJ	B-NP
O	1765	1766	c	c	NN	I-NP
O	1766	1767	-	-	HYPH	B-NP
O	1767	1771	FLIP	FLIP	NN	I-NP
O	1772	1775	and	and	CC	O
O	1776	1781	TRAIL	TRAIL	NN	B-NP
O	1782	1792	expression	expression	NN	I-NP
O	1793	1796	may	may	MD	B-VP
O	1797	1799	be	be	VB	I-VP
O	1800	1811	independent	independent	JJ	B-NP
O	1812	1819	adverse	adverse	JJ	I-NP
O	1820	1830	prognostic	prognostic	JJ	I-NP
O	1831	1838	markers	marker	NNS	I-NP
O	1839	1841	in	in	IN	B-PP
B-Cancer	1842	1847	stage	stage	NN	B-NP
I-Cancer	1848	1850	II	II	CD	I-NP
I-Cancer	1851	1854	and	and	CC	I-NP
I-Cancer	1855	1858	III	III	CD	I-NP
I-Cancer	1859	1869	colorectal	colorectal	JJ	I-NP
I-Cancer	1870	1876	cancer	cancer	NN	I-NP
O	1877	1880	and	and	CC	O
O	1881	1886	might	might	MD	B-VP
O	1887	1895	identify	identify	VB	I-VP
O	1896	1904	patients	patient	NNS	B-NP
O	1905	1909	most	most	RBS	B-ADVP
O	1910	1912	at	at	IN	B-PP
O	1913	1917	risk	risk	NN	B-NP
O	1918	1920	of	of	IN	B-PP
O	1921	1928	relapse	relapse	NN	B-NP
O	1928	1929	.	.	.	O

